PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go:
Stretch
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
QFinds is a purpose-built hiring tool that enables employers to easily and efficiently pre-screen candidates, conduct interviews and generate employment contracts. The company asserts that it is a UK government vetted 'Kickstart Scheme' representative and can get small businesses grants to hire interns having already processed over 100 job applications. QFinds claims that its app has been downloaded 2 million+ times garnering 24,000 reviews averaging 4.8/5 stars. QFinds also points out that bad hirings cost the UK up to £6.7 billion in turnover, productivity, and training. It seeks to change this and disrupt the £39 billion recruitment market. The company has partnered with notable entities like University College London, Kings College London and Brunel University London, intending to use them as strategic partners to increase job seekers signing up to and using its app. QFinds will use the investment to grow its business across different verticals.
days to go:
Expired
investment:
£222,866
IO-CO is an ideation company engaged in reducing the risk of launching consumer products. With its unique designing and prototyping methods, it allows market validation at a very early stage in the development cycle. Within a short span of 7 months, IO-CO is ready to commercialise 4 new products and is on the brink of forming an alliance with a sizable financial and technical partner.
days to go:
Expired
investment:
£430,005
Integumen is a personal health company developing and commercialising technology and products for the human integumentary system that may improve physical appearance, hygiene and general health outcomes.
days to go:
Expired
investment:
£2,160,000
MedicSpot is a healthcare company that is aiming to revolutionise healthcare delivery by combining the advantages of online and offline care. The company provides patients at designated hospitals with diagnostic tools like a stethoscope, oximeter, blood pressure monitor and thermometer which, in turn, is connected to the MedicSpot network. Onboard General Physicians (GPs) engage in live sessions with patients, guide them on how to use the tools, and perform a variety of diagnoses like listening to a patient’s heart and lungs, looking down their throat and into their ears, taking their blood pressure and oxygen readings, and measuring their body temperature. The company is also expanding into another subsidiary, Arc Health, which it claims will perform the aforementioned tasks with more efficiency and accuracy. The company will use the investment to increase the number of Medicspot clinics to 1,000, gain further NHS market share, launch a corporate business model and allow international pilots to take place.
days to go:
Expired
investment:
£1,048,396
Senta assists accountants in managing and running their practices by using a cloud-based service. The software aids the accountant with marketing and CRM, scheduling tasks and deadlines, as well as providing excellent customer service and improving security. This solution eases their admin burden, which allows more time to be spent finding new businesses and increasing productivity and efficiency in their daily workflow.
days to go:
Expired
investment:
£540,251
Doctaly is the brand new healthcare platform providing the quickest way to find and book an affordable, face-to-face, same day GP appointment. Choose from their trusted private doctors, at a convenient time and location from just £39.99.
days to go:
Expired
investment:
£807,580
